{"id":152496,"date":"2022-12-11T19:23:16","date_gmt":"2022-12-12T01:23:16","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/12\/experimental-cancer-therapy-shows-success-in-more-than-70-of-patients-in-global-clinical-trials"},"modified":"2022-12-11T19:23:16","modified_gmt":"2022-12-12T01:23:16","slug":"experimental-cancer-therapy-shows-success-in-more-than-70-of-patients-in-global-clinical-trials","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/12\/experimental-cancer-therapy-shows-success-in-more-than-70-of-patients-in-global-clinical-trials","title":{"rendered":"Experimental cancer therapy shows success in more than 70% of patients in global clinical trials"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/experimental-cancer-therapy-shows-success-in-more-than-70-of-patients-in-global-clinical-trials2.jpg\"><\/a><\/p>\n<p>A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.<\/p>\n<p>The therapy, known as a bispecific antibody, binds to both T cells and multiple <a href=\"https:\/\/medicalxpress.com\/tags\/myeloma+cells\/\" rel=\"tag\" class=\"\">myeloma cells<\/a> and directs the T cells\u2014 <a href=\"https:\/\/medicalxpress.com\/tags\/white+blood+cells\/\" rel=\"tag\" class=\"\">white blood cells<\/a> that can be enlisted to fight off diseases\u2014to kill multiple <a href=\"https:\/\/medicalxpress.com\/tags\/myeloma\/\" rel=\"tag\" class=\"\">myeloma<\/a> cells. The researchers described this strategy as \u201cbringing your army right to the enemy.\u201d<\/p>\n<p>The success of the off-the-shelf immunotherapy, called talquetamab, was even seen in patients whose <a href=\"https:\/\/medicalxpress.com\/tags\/cancer\/\" rel=\"tag\" class=\"\">cancer<\/a> was resistant to all approved multiple myeloma therapies. It uses a different target than other approved therapies: a receptor expressed on the surface of cancer cells known as GPRC5D.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. The therapy, known as a bispecific antibody, binds to both T cells [\u2026]<\/p>\n","protected":false},"author":427,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-152496","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/152496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/427"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=152496"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/152496\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=152496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=152496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=152496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}